Related Experiment Videos
Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma
A Lafeuillade1, C Poggi, N Profizi
1Department of Infectious Diseases, General Hospital, Toulon, France.
The Journal of Infectious Diseases
|August 1, 1996
Summary
This study measured human immunodeficiency virus type 1 (HIV-1) RNA decline in plasma and lymph nodes of patients on triple-drug therapy. Results show HIV-1 RNA reduction in both compartments, indicating treatment effectiveness against viral reservoirs.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- Lymphoid organs are primary reservoirs for human immunodeficiency virus type 1 (HIV-1).
- Understanding HIV-1 dynamics in lymphoid tissues is crucial for effective treatment strategies.
Purpose of the Study:
- To quantify the decay rates of HIV-1 RNA in plasma and lymph nodes.
- To assess the impact of a specific triple-drug combination therapy on HIV-1 reservoirs.
Main Methods:
- Measurement of HIV-1 RNA concentrations in plasma and serial lymph node biopsies.
- Analysis of exponential decay rates and half-lives for HIV-1 RNA.
- Treatment involved a combination of zidovudine, didanosine, and lamivudine.
Main Results:
- HIV-1 RNA concentrations declined exponentially in both plasma and lymph nodes.
- Mean plasma half-life was 1.88 +/- 0.86 days.
- Mean lymph node half-life was 6.01 +/- 3.44 days.
Conclusions:
- The majority of HIV-1 in lymphoid organs results from new cell infections.
- The studied triple-drug combination therapy effectively targets HIV-1 within lymphoid compartments.